Equity (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2020

Dec. 31, 2019

Equity [Abstract]

Schedule of Convertible Preferred Shares

As of September 30, 2020, the number of preferred shares and the amount each class is convertible into is below:

	Number of Preferred Stock		Number of underlying Common stock
Series B Convertible Preferred Stock		17,303		2,220,552	*
Series C Convertible Preferred Stock		2,343		33,322
Total				2,253,874

* Including the shares of common stock the holders of Series B Convertible Preferred Stock are entitled to receive as cumulative dividends at the rate per share of 15% per annum of the stated value for five years, payable in cash or common stock, at the Company’s discretion, but excluding effect of future conversion price adjustment, if any.

As of December 31, 2019, the Number of Preferred shares the amount each class is convertible into is below:

	Number of Preferred Stock		Number of underlying Common stock
Series B Convertible Preferred Stock		17,303		555,138	*
Series C Convertible Preferred Stock		34,370		122,204
Total				677,342

* Including the shares of common stock the holders of Series B Convertible Preferred Stock are entitled to receive as cumulative dividends at the rate per share of 15% per annum of the stated value for five years, payable in cash or common stock, at the Company’s discretion, but excluding effect of future conversion price adjustment, if any.

Schedule of Warrants Outstanding Activity

As of September 30, 2020, the Company has outstanding warrants to purchase an aggregate of 26,705,502 shares of common stock as follows:

	Number of underlying Common stock		Weighted average exercise price
Series A Warrants		1,107	$	8,750.00
Series B Warrants		2,448	$	3,500.00
Series D Warrants		766,698	$	15.00
Series E Warrants		2,972,221	$	1.80
Series F Warrants		22,688,900	$	0.50
Underwriter Warrants		274,029	$	0.50
Other warrants		99	$	21,993.00
Total Warrants		26,705,502	$	1.82

As of December 31, 2019, the Company has outstanding warrants to purchase an aggregate of 4,016,817 shares of common stock as follows:

	Number of underlying Common stock		Weighted average exercise price
Series A Warrants		1,102	$	8,750.00
Series B Warrants		2,448	$	3,500.00
Series D Warrants		806,698	$	15.19
Series E Warrants		2,972,221	$	1.80
April 2019 Underwriter Warrants		34,955	$	6.25
September 2019 Underwriter Warrants		194,444	$	2.25
Other warrants		4,949	$	11,258.00
Total Warrants		4,016,817	$	22.95

Schedule of Stock Options Granted

The following table summarizes information about stock options granted to employees:

	Year ended December 31
	2019					2018
	Number of options			Weighted average exercise price		Number of options			Weighted average exercise price
Outstanding - beginning of period		164		$	184,656		220		$	247,835
Granted		-
Forfeited		(4	)		4,423		(56	)		432,861
Exercised		-			-
Outstanding -end of period		160		$	189,162		164		$	184,656
Exercisable at the end of the period		160		$	189,162		139		$	216,819

The following table summarizes information about stock options granted to non-employees:

	Year ended December 31
	2019					2018
	Number of options			Weighted average exercise price		Number of options			Weighted average exercise price
Outstanding - beginning of period		20		$	1,693,174		24		$	1,542,073
Granted		-			-		-			-
Forfeited		(4	)		1,617,338		(4	)		786,556
Exercised		-			-		-			-
Outstanding - end of period		16			1,711,975		20		$	1,693,174
Exercisable at the end of the period		16			1,711,975		18		$	1,689,533

Schedule of Information About Restricted Shares to Employees

The following table summarizes information about restricted stock granted to employees:

	Year ended December 31
	2019			2018
	Number of restricted stock
Outstanding - beginning of period		19			48
Reverse Split Adjustments		(127	)		0
Granted		70,582			0
Forfeited		(838	)		(8	)
Vested		(5	)		(21	)
Outstanding - end of period		69,631			19

Schedule of Warrants and Options Outstanding and Exercisable

The following table provides additional information about all options outstanding and exercisable:

	Outstanding as of December 31, 2019
Exercise price	Options outstanding		Weighted average remaining contractual life (years)		Options exercisable
$0		2		2.40		2
$175 and above		174		5.89		174
		176		5.85		176

Schedule of Allocation of Total Share-based Compensation Expense

The following table summarizes the allocation of total share-based compensation expense in the consolidated statements of operations:

	Year ended December 31
	2019		2018
	($ in thousands)
Cost of revenues	$	14	$	4
Research and development		10		-
Sales and marketing		29		6
General and administrative		272		60
	$	325	$	70